Second chance: nonconforming CAR-T therapy offered to lymphoma patients
NCT ID NCT04400591
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This program provides access to a CAR-T cell therapy called lisocabtagene maraleucel (liso-cel) that didn't meet all commercial quality standards. It is for adults with large B-cell lymphoma who were already prescribed liso-cel as part of their care. Patients receive chemotherapy before the treatment, and the goal is to offer a potential benefit when no other options are available.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, LARGE B-CELL, DIFFUSE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact